Following a 12-week low FODMAP diet intake, the participants exhibited a significant induction in circulating GLP-1 levels (increasing modestly from about 3.3 pM to 3.6 pM), significantly reduced body weight, and significantly improved IBS and gastrointestinal symptoms
Shes more confident than ever.
Reference Novo Nordisk A/S: Wegovy pill approved in the US as first oral GLP-1 for weight management, 23 December 2025, Can oral Semaglutide (Wegovy) 25 mg replace the Once-Weekly 2.4 mg Injection for Obesity?, 25 September 2025, Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range (OASIS 4), ClinicalTrials.gov ID NCT05564117, Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, Shaji C, Rubino D, Garvey WT
A 72-week trial in adults with obesity found an average of 20.2% change in body weight with tirzepatide versus 13.7% with semaglutide